HeaDS

Athens, Greece Founded: 2010 • Age: 16 yrs Acquired By Veeda Clinical Research
Pharmacovigilance, regulatory affairs, and quality assurance services are provided.
Annual revenue $50.5M Latest available
Total funding - Funding intelligence
Employees 902 Tracked headcount
Investors 1 Known backers
Products 4 Services tracked
Competitors 8 Brand Intelligence

About HeaDS

HeaDS is a company based in Athens (Greece) founded in 2010 was acquired by Veeda Clinical Research in March 2024. The company has 902 employees as of November 04, 2024. HeaDS offers products and services including Preclinical Services, Clinical Trials, Bioanalytical Services, and Real World Evidence. HeaDS operates in a competitive market with competitors including Indegene, Zuellig Pharma, IntegriChain, Clinigen and Science Group, among others.

  • Headquarter Athens, Greece
  • Employees 902 as on 04 Nov, 2024
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Veeda Clinical Research Limited
  • Jurisdiction Ahmedabad, Gujarat, India
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $50.52 M (USD)
    43.36
    as on Mar 31, 2023
  • Net Profit
    $5.1 M (USD)
    -15.92
    as on Mar 31, 2023
  • EBITDA
    $12.43 M (USD)
    68.37
    as on Mar 31, 2023
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    902

    as on Nov 04, 2024

  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of HeaDS

HeaDS offers a comprehensive portfolio of products and services, including Preclinical Services, Clinical Trials, Bioanalytical Services, and Real World Evidence.

Product name locked
Category locked
Primary

Supports drug discovery and IND submission processes.

Product name locked
Category locked
Locked

Conducts phases I-IV trials for various therapeutics.

Product name locked
Category locked
Locked

Handles method development and sample analysis for drugs.

Product name locked
Category locked
Locked

Uses real-world data to improve trial recruitment and outcomes.

People of HeaDS

Headcount 50-200
Employee Profiles 15
Employee Profiles
People
Chiranjeeb Das
Head Of Clinical Data Management Processes
People
George Pramantiotis
Data Engineer | Clinical Engineer
People
Marieta Riga
Senior Clinical Operations Manager
People
Argiris Papaioannou
Clinical Informatics

Unlock access to complete

Funding Insights of HeaDS

Premium access

Detailed funding history for HeaDS

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in HeaDS

HeaDS has secured backing from 1 investor. Prominent investors backing the company include Veeda Clinical Research.

All
Investor Description Founded Year Domain Location
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare.
Locked Locked Locked
Premium access

Investor details for HeaDS

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by HeaDS

Investments
Premium access

Investment portfolio details for HeaDS

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - HeaDS

Premium access

Detailed financials for HeaDS

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Heads Comparisons

HeaDS Primary company
Description
Pharmacovigilance, regulatory affairs, and quality assurance...
Location
Athens, Greece
Founded Year
2010
Annual Revenue
$50.52 M (USD)
Net Profit
$5.1 M (USD)
EBITDA
$12.43 M (USD)
Employees
902
As of 2024
Premium access

Peer comparison for HeaDS

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of HeaDS

HeaDS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indegene, Zuellig Pharma, IntegriChain, Clinigen and Science Group, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Suite solutions are provided for payers and healthcare providers.
Locked Locked Locked
Healthcare access in Asia is enhanced by Zuellig Pharma.
Locked Locked Locked
Inventory, order and customer relationship management solution for life science suppliers.
Locked Locked Locked
Specialty medicines are supplied via clinical trials and access programs.
Locked Locked Locked
Technology-based consultancy and product development services are provided.
Locked Locked Locked
Strategic consulting services are provided to life sciences companies.
Premium access

Detailed competitors of HeaDS

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Heads

Premium access

Complete news archive for HeaDS

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about HeaDS

HeaDS was founded in 2010.

HeaDS is headquartered in Athens, Greece.

As of Nov 04, 2024, the latest employee count at HeaDS is 902.

Annual revenue of HeaDS is $50.52M as on Mar 31, 2023.

HeaDS was founded in 2010 and is based in Athens, Greece. Services in pharmacovigilance, regulatory affairs, and quality assurance are offered to clients in the pharmaceutical and healthcare sectors. Operations are centered on compliance support, risk management, and documentation processes. The company serves international markets through its domain heads-research.com, with a focus on regulatory submissions and safety monitoring. Expertise is applied to ensure adherence to global standards.

HeaDS's top competitors include Indegene, Zuellig Pharma and IntegriChain.

HeaDS offers Preclinical Services, Clinical Trials, Bioanalytical Services, and Real World Evidence.

HeaDS has 1 investor. Key investors include Veeda Clinical Research.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available